Although there is substantial risk to maternal and neonatal health in the situation of pregnancy during treatment for rifampicin-resistant tuberculosis (RR-TB), there is little evidence to guide clinicians as to how to manage this complexity. Of the 49 680 patients initiated on RR-TB treatment from 2009 to 2014 in South Africa, 47% were women and 80% of them were in their reproductive years (15 -44). There is an urgent need for increased evidence of the safety of RR-TB treatment during pregnancy, increased access to contraception during RR-TB treatment, and inclusion of reproductive health in research on the prevention and treatment of TB.
An analysis of the global burden of tuberculosis (TB) during pregnancy estimated that each year, more than 8 400 pregnant women in South Africa (SA) have active TB. [1] To put this burden into context, across sub-Saharan Africa, the combination of TB and HIV in pregnancy is a leading cause of maternal mortality [2] and in SA an estimated 65% of TB patients are HIV-positive. SA also ranks among the top countries in the world in terms of the number of TB patients with rifampicinresistant TB (RR-TB), [3] including multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB. RR-TB requires 18 -24 months of complex treatment with a high frequency of adverse drug reactions and poor treatment outcomes. Globally less than 50% of the 2011 cohort of MDR-TB patients were treated successfully. [3] Globally, there is scant evidence on the safety of second-line TB medications during pregnancy. Clinicians rely on data extrapolated from decades-old clinical trials [4] or from limited case series. [5] Clinicians must weigh the scant safety data against evidence that delayed RR-TB treatment may increase the risk of obstetric and neonatal complications from TB disease, [6] ongoing transmission, and that suboptimal RR-TB treatment can lead to failure and the amplification of resistance.
Estimating the burden of pregnancy during RR-TB treatment in SA
In order to quantify the risk of pregnancy and RR-TB treatment, we analysed the drug-resistant TB case registry in SA to assess the number of women receiving RR-TB during their reproductive years.
Setting and treatment guidelines
SA RR-TB patients receive a standardised regimen: 6 months of an injectable drug (kanamycin or amikacin) and 18 -24 months of moxifloxacin, ethionamide, terizidone and pyrazinamide. Patients with second-line drug resistance, toxicity, or contraindications to the standardised regimen can access individualised regimens including capreomycin, para-aminosalicylic acid, clofazimine, linezolid and bedaquiline. SA has universal testing for rifampicin resistance with public sector coverage of Xpert MTB/RIF since the end of 2013.
Data extraction and analysis
The Electronic DR-TB Register (EDRweb) is the RR-TB national case register and, since 2012, has been used for reporting to the World Health Organization (WHO). A census of patients registered in the EDRweb from January 2009 to December 2014 was exported (N=53 623). Registrations missing sex, report of rifampicin resistance or date of treatment initiation details were excluded. Pregnancy and pregnancy outcomes are not routinely reported in the EDRweb.
Descriptive counts and proportions for gender, age category (0 -14, 15 -29, 30 -44, 45 -59, 60+), HIV status (negative, positive or unknown), history of prior TB treatment with any outcomes, and category of drug resistance (RR-TB and MDR-TB or secondline drug resistance as indicated by XDR-TB case registration) are presented. Differences of proportions were estimated using Pearson's χ 2 and p-values are presented. All analyses were conducted in Stata SE version 13 (College Station, USA).
Ethical approval
The University of the Witwatersrand Human Research Ethics Committee approved this retrospective, de-identified, secondary analysis in April 2015.
Results
From 2009 to 2014, 49 680 patients with RR-TB were registered and initiated on second-line TB treatment in the EDRweb. Nearly half (47.2%, n=23 428) were female. Males had a median age of 37 (interquartile range (IQR) 30 -45) years and females a median age of 32 (IQR 26 -40) years. Eighty percent (n=18 750) of the women treated for RR-TB were aged 15 -44 years.
At initiation of RR-TB treatment ( 
An urgent call to action
From 2009 to 2014, 23 428 women initiated RR-TB treatment in SA. Of these women on second-line TB treatment, 80% were of reproductive age. In contrast, a 2012 review of TB treatment in pregnant and postpartum women found only eight published case reports to guide second-line TB treatment during pregnancy, describing outcomes for 73 women. [5] Most (68.0%) of the women treated for RR-TB in SA are also HIV-positive, yet the case reports describe outcomes for just six HIV-positive women. [5] These numbers should serve as an urgent call to action:
1. Collect more evidence of the safety of second-line TB treatment during pregnancy Mothers with RR-TB and their clinicians are faced with a difficult decision. Should they treat the mother's RR-TB and expose the fetus to potentially toxic drugs, or delay or stop treatment and face the risk of maternal or fetal mortality or the amplification of drug resistance? The principal concern is ototoxicity related to the injectable drugs, among the mainstays of second-line TB treatment. More evidence of the safety of second-line TB treatment during pregnancy is urgently needed to inform these decisions. This is a broader call than adverse drug event monitoring given the importance of also reporting the outcomes of TB and pregnancy even in the absence of adverse drug events. Monitoring RR-TB and pregnancy outcomes requires co-ordination across different facilities and health directorates, as women need to be identified during antenatal care and followed through delivery and postpartum. The drugs-exposure pregnancy register led by the WHO can serve as a model of a feasible system for resourcelimited contexts. [7] 2. Ensure access to effective contraception during second-line TB treatment Currently, contraception services in SA are offered at primary healthcare level while RR-TB services are more centralised, often still at hospital level. Offering effective contraception to women on second-line TB treatment could reduce the number of pregnancies during active TB. Integration of family planning services within the RR-TB units is therefore urgently needed.
Ensure women's health is included in
research on prevention and treatment of TB Effective TB research is the third pillar of the WHO strategy to end TB. This research must address women's health, especially reproductive health. More information and evidence on effective TB prophylaxis for women and infants, pharmacokinetics of TB drugs in pregnancy and pharmacokinetics of contraceptives and antiretrovirals during TB treatment is needed urgently. [8] 
Conclusion
In SA, where the burden of RR-TB and TB/ HIV co-infection is high, there is an urgent need for increased evidence of the safety of RR-TB treatment during pregnancy. Increased access to contraception during RR-TB treatment and inclusion of reproductive health in research on the prevention and treatment of TB need to be addressed. The funders had no role in the study design, collection, analysis and interpretation of the data, in manuscript preparation or in the decision to publish. 
